Clinical Trials Logo
  1. Home
  2. Membranous Nephropathy
  3. NCT00518219

To Compare the Efficacy and Safety of Tripterygium Wilfordii (TW) Versus Valsartan in the Membranous Nephropathy (MN)

Membranous Nephropathy Clinical Trial

Official title:
To Compare the Efficacy and Safety of TW vs Valsartan in the MN

Clinical Trial Summary

The purpose of this study is to assess the efficacy of TW compared to Valsartan in treatment of heavy proteinuria of membranous nephropathy.

Clinical Trial Description

Membranous nephropathy with heavy proteinuria have high risks of progressing to CRF.

Tripterygium (TW) is a Chinese traditional patent drugs, it can reduce proteinuria of chronic glomerular nephritis,such as IgA nephropathy. So, we designed this randomized, prospective clinical trial to assess the efficacy and safety of TW versus Valsartan in the treatment of heavy proteinuria of MN. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00518219
Study type Interventional
Source Nanjing University School of Medicine
Contact
Status Completed
Phase Phase 4
Start date July 2007
Completion date September 2009
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04095156 - Autoreactive B Cells in Membranous Nephropathy
Not yet recruiting NCT06341205 - Personalized Rituximab Treatment Based on Artificial Intelligence in Membranous Nephropathy (iRITUX) Phase 3
Active, not recruiting NCT04893096 - MOR202 for Refractory MN Phase 2
Completed NCT00405340 - Rituximab in the Treatment of Idiopathic Membranous Nephropathy Phase 0
Recruiting NCT06065852 - National Registry of Rare Kidney Diseases
Active, not recruiting NCT04652570 - Efficacy and Safety of VB119 in Subjects With Membranous Nephropathy Phase 1/Phase 2
Not yet recruiting NCT06242327 - An Outcome Analysis of Primary Membranous Nephropathy
Recruiting NCT03929887 - KOrea Renal Biobank NEtwoRk System TOward NExt-generation Analysis
Active, not recruiting NCT03949855 - Belimumab With Rituximab for Primary Membranous Nephropathy Phase 2
Completed NCT00983034 - The Effects of Helicobacter Pylori Eradication on Proteinuria in Patients With Membranous Nephropathy N/A
Completed NCT03025828 - Adrenocorticotropic Hormone in Membranous Nephropathy Phase 4
Recruiting NCT05732402 - An Open-label Study of Povetacicept (ALPN-303) in Autoimmune Kidney Diseases Phase 1/Phase 2
Enrolling by invitation NCT04571658 - NEPTUNE Match Study
Active, not recruiting NCT05894512 - Analysis of T- and B-Cell Subpopulations in Membranous Nephropathy
Not yet recruiting NCT05941845 - Interferon Alfa Therapy Based on Th17 Profile in Membranous Nephropathy Phase 2
Completed NCT02199145 - Role of Anti-mouse PLA2R1 ELISA in Membranous Nephropathy N/A
Not yet recruiting NCT04326218 - Immunopathological Analysis in a French National Cohort of Membranous Nephropathy N/A
Active, not recruiting NCT03453619 - Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies Phase 2
Completed NCT01955187 - Sequential Therapy With Tacrolimus and Rituximab in Primary Membranous Nephropathy Phase 3
Completed NCT04733040 - Efficacy, Safety and PK/PD of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN) (NewPLACE) Phase 2